These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37539782)

  • 1. Association of Remdesivir use with bradycardia: A systematic review and meta-analysis.
    Ishisaka Y; Aikawa T; Malik A; Kampaktsis PN; Briasoulis A; Kuno T
    J Med Virol; 2023 Aug; 95(8):e29018. PubMed ID: 37539782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study.
    Schreiber A; Bauzon JS; Batra K; Mohammed S; Lee K; Houshmand N; Pham U; Cosme C; Inciong K; Al-Taweel O; Nasser K; Rana J; Sossou C; Go A; Hawwass D; Diep J; Ahsan CH
    Clin Drug Investig; 2022 Sep; 42(9):763-774. PubMed ID: 35978159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center.
    Chang HY; Hsu CC; Hu LF; Chou CY; Chang YL; Lu CC; Chang LJ
    Ann Med; 2024 Dec; 56(1):2361843. PubMed ID: 38830017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sinus Bradycardia in a Pediatric Patient Treated With Remdesivir for Acute Coronavirus Disease 2019: A Case Report and a Review of the Literature.
    Chow EJ; Maust B; Kazmier KM; Stokes C
    J Pediatric Infect Dis Soc; 2021 Oct; 10(9):926-929. PubMed ID: 34173663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir for the treatment of COVID-19: a living systematic review.
    Verdugo-Paiva F; Acuña MP; Solá I; Rada G;
    Medwave; 2020 Dec; 20(11):e8080. PubMed ID: 33361753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir Use in Pediatric Patients for SARS-CoV-2 Treatment: Single Academic Center Study.
    Samuel AM; Hacker LL; Zebracki J; Bogenschutz MC; Schulz L; Strayer J; Vanderloo JP; Cengiz P; Henderson S
    Pediatr Infect Dis J; 2023 Apr; 42(4):310-314. PubMed ID: 36728726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism.
    Filtz A; Carandina A; Fasiello A; Barbetta L; Lombardi R; Cinque F; Rizzi G; Ceriani E; Furlan L; Bellocchi C; Fracanzani AL; Hu C; Cogliati C; Canetta C; Peyvandi F; Montano N; Tobaldini E
    Intern Emerg Med; 2023 Mar; 18(2):359-366. PubMed ID: 36539604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience.
    Attena E; Caturano A; Annunziata A; Maraolo AE; De Rosa A; Fusco FM; Halasz G; Dall'Ospedale V; Conte M; Parisi V; Galiero R; Sasso FC; Fiorentino G; Russo V
    Eur J Clin Pharmacol; 2023 Jul; 79(7):967-974. PubMed ID: 37212843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir-induced bradycardia in a 26-year-old patient with COVID-19: a case report.
    Guziejko K; Talalaj J; Chorazy M; Groth M; Moniuszko-Malinowska A
    Infection; 2022 Dec; 50(6):1605-1613. PubMed ID: 35701724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
    Singh A; Kamath A
    Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
    [No Abstract]   [Full Text] [Related]  

  • 13. Transient asymptomatic bradycardia and remdesivir in COVID-19 patients.
    Adamo G; Amata M; Cannizzaro N; Chessari C; Sapienza GM; Capizzi GM; Battaglia S; Benfante A; Scichilone N
    Minerva Med; 2023 Aug; 114(4):463-468. PubMed ID: 35332758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study.
    Attena E; Albani S; Maraolo AE; Mollica M; De Rosa A; Pisapia R; Fiorentino G; Parrella R; Severino S; Russo V
    Circ Arrhythm Electrophysiol; 2021 Jul; 14(7):e009811. PubMed ID: 34182791
    [No Abstract]   [Full Text] [Related]  

  • 15. Precipitating factors of bradycardia after remdesivir administration: ICU admission and cutoff value for declining heart rate.
    Chen YZ; Lin MS; Lin YP; Liu YZ; Yang CJ
    J Microbiol Immunol Infect; 2023 Oct; 56(5):970-976. PubMed ID: 37407291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remdesivir-Induced Bradycardia and Mortality in SARS-CoV-2 Infection, Potential Risk Factors Assessment: A Systematic Review and Meta-Analysis.
    Ai MY; Chang WL; Yang CJ
    J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137586
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
    Tasavon Gholamhoseini M; Yazdi-Feyzabadi V; Goudarzi R; Mehrolhassani MH
    J Pharm Pharm Sci; 2021; 24():237-245. PubMed ID: 34048669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.